100 related articles for article (PubMed ID: 20209452)
1. Clinical relevance of HER-2/neu overexpression in patients with testicular nonseminomatous germ cell tumor.
Ghavamnasiri MR; Saeedi Saedi H; Shahid Sales S; Ghafarzadegan K
Urol J; 2010; 7(1):26-9. PubMed ID: 20209452
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of HER-2/neu expression in germ-cell testicular tumors.
Mándoky L; Géczi L; Bodrogi I; Tóth J; Csuka O; Kásler M; Bak M
Anticancer Res; 2004; 24(4):2219-24. PubMed ID: 15330164
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors.
Moroni M; Veronese S; Schiavo R; Carminati O; Sorensen BS; Gambacorta M; Siena S
Clin Cancer Res; 2001 Sep; 7(9):2770-5. PubMed ID: 11555591
[TBL] [Abstract][Full Text] [Related]
4. Expression of HER-2/neu in testicular tumors.
Mandoky L; Geczi L; Bodrogi I; Toth J; Bak M
Anticancer Res; 2003; 23(4):3447-51. PubMed ID: 12926088
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
[TBL] [Abstract][Full Text] [Related]
6. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.
Coogan CL; Estrada CR; Kapur S; Bloom KJ
Urology; 2004 Apr; 63(4):786-90. PubMed ID: 15072912
[TBL] [Abstract][Full Text] [Related]
8. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
Saffari B; Jones LA; el-Naggar A; Felix JC; George J; Press MF
Cancer Res; 1995 Dec; 55(23):5693-8. PubMed ID: 7585656
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
Kim YS; Konoplev SN; Montemurro F; Hoy E; Smith TL; Rondón G; Champlin RE; Sahin AA; Ueno NT
Clin Cancer Res; 2001 Dec; 7(12):4008-12. PubMed ID: 11751494
[TBL] [Abstract][Full Text] [Related]
10. p53 and HER-2/neu overexpression in ovarian borderline tumors.
Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR
Gynecol Oncol; 1997 May; 65(2):218-24. PubMed ID: 9159328
[TBL] [Abstract][Full Text] [Related]
11. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
[TBL] [Abstract][Full Text] [Related]
12. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
14. Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines.
Jones J; Lagasse LD; Karlan BY
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):421-6. PubMed ID: 7835782
[TBL] [Abstract][Full Text] [Related]
15. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness.
Goebel SU; Iwamoto M; Raffeld M; Gibril F; Hou W; Serrano J; Jensen RT
Cancer Res; 2002 Jul; 62(13):3702-10. PubMed ID: 12097278
[TBL] [Abstract][Full Text] [Related]
16. Her-2/neu expression in testicular cancer--a retrospective analysis in 57 cases.
Pfister D; Richter S; Thüer D; Giedl J; Heidenreich A; Klotz T
Urology; 2010 Nov; 76(5):1266.e6-9. PubMed ID: 21056276
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-beta expression in human testicular germ cell tumors.
Pais V; Leav I; Lau KM; Jiang Z; Ho SM
Clin Cancer Res; 2003 Oct; 9(12):4475-82. PubMed ID: 14555521
[TBL] [Abstract][Full Text] [Related]
18. Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors.
Forseen SE; Potti A; Koka V; Koch M; Fraiman G; Levitt R
Anticancer Res; 2002; 22(3):1599-602. PubMed ID: 12168843
[TBL] [Abstract][Full Text] [Related]
19. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
20. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]